Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

The therapy failed to slow disease progression in patients with early Alzheimer’s in the INVOKE-2 trial (NCT04592874).

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues ...

In this new analysis, the Company reported changes in plasma biomarkers that may reflect Alzheimer's disease pathology. The results demonstrated that individuals who entered the study with plasma ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...